APOE genotype, lipids, and coronary heart disease risk: A prospective population study

Archives of Internal Medicine

Volumn 169, Issue 15, 2009, Pages 1424-1429

  Ward, Heather ^a,f   Mitrou, Panagiota N ^a,b   Bowman, Richard ^c,e   Luben, Robert ^a   Wareham, Nicholas J ^a,d   Khaw, Kay Tee ^a   Bingham, Sheila ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WORLD CANCER RESEARCH FUND INTERNATIONAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HAZARD RATIO; HOMOZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ALLELES; APOLIPOPROTEINS E; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 68849125142     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.234     Document Type: Article

References (39)

1. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8(1):1-21.
2. Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994;35(5):779-792.
3. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985;37(2): 268-285.
4. Minihane AM, Jofre-Monseny L, Olano-Martin E, Rimbach G. ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc Nutr Soc. 2007;66(2):183-197.
5. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141(2):137-147.
6. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol. 1996; 16(10):1250-1255.
7. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298(11):1300-1311.
8. Wu K, Bowman R, Welch AA, et al. Apolipoprotein E polymorphisms, dietary fat and fibre, and serum lipids: the EPIC Norfolk study. Eur Heart J. 2007;28(23): 2930-2936.
9. Elosua R, Ordovas JM, Cupples LA, et al. Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. J Lipid Res. 2004;45(10):1868-1875.
10. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis. 2001;154 (3):529-537.
11. Lewis SJ, Brunner EJ. Methodological problems in genetic association studies of longevity - the apolipoprotein E gene as an example. Int J Epidemiol. 2004; 33(5):962-970.
12. Djoussé L, Myers RH, Province MA, et al. Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke. 2002;33(5):1357-1361.
13. Frikke-Schmidt R, Tybjaerg-Hansen A, Steffensen R, Jensen G, Nordestgaard BG. Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol. 2000;35(5):1192-1199.
14. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358(9276):115-119.
15. Humphries SE, Hawe E, Dhamrait S, Miller GJ, Talmud PJ. In search of genetic precision. Lancet. 2003;361(9372):1908-1909, author reply 1909-1910.
16. Karvonen J, Kauma H, Kervinen K, et al. Apolipoprotein E polymorphism affects carotid artery atherosclerosis in smoking hypertensive men. J Hypertens. 2002; 20(12):2371-2378.
17. Scuteri A, Bos AJ, Zonderman AB, Brant LJ, Lakatta EG, Fleg JL. Is the apoE4 allele an independent predictor of coronary events? Am J Med. 2001;110(1): 28-32.
18. Talmud PJ, Lewis SJ, Hawe E, et al. No APOEε4 effect on coronary heart disease risk in a cohort with low smoking prevalence: the Whitehall II study. Atherosclerosis. 2004;177(1):105-112.
19. Talmud PJ, Stephens JW, Hawe E, et al. The significant increase in cardiovascular disease risk in APOEε4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet. 2005;69(pt 6):613-622.
20. Volcik KA, Barkley RA, Hutchinson RG, et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol. 2006;164(4):342-348.
21. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999; 80(suppl 1):95-103.
22. Wareham NJ, Jakes RW, Rennie KL, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation Into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003;6(4):407-413.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
24. Loktionov A, Bingham SA, Vorster H, Jerling JC, Runswick SA, Cummings JH. Apolipoprotein E genotype modulates the effect of black tea drinking on blood lipids and blood coagulation factors: a pilot study. Br J Nutr. 1998;79(2):133-139.
25. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res. 1992;33(4):447-454.
26. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257(5):2518-2521.
27. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
28. Mamotte CD, Sturm M, Foo JI, van Bockxmeer FM, Taylor RR. Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes. Am J Physiol. 1999;276(3, pt 1):E553-E557.
29. Miettinen TA, Gylling H, Vanhanen H, Ollus A. Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes. Arterioscler Thromb. 1992;12(9):1044-1052.
30. Mamotte CD, Burke V, Taylor RR, van Bockxmeer FM. Evidence of reduced coronary artery disease risk for apolipoprotein ε2/3 heterozygotes. Eur J Intern Med. 2002;13(4):250-255.
31. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA. 1994;272(21):1666-1671.
32. Liu S, Ma J, Ridker PM, Breslow JL, Stampfer MJ. A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis. 2003;166(2):323-329.
33. Keavney B, Parish S, Palmer A, et al; International Studies of Infarct Survival (ISIS) Collaborators. Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E ε2/ε3/ε4 genotype. Lancet. 2003; 361(9355):396-398.
34. Keavney B, Palmer A, Parish S, et al; International Studies of Infarct Survival (ISIS) Collaborators. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol. 2004;33(5):1002-1013.
35. Luc G, Bard JM, Arveiler D, et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: the ECTIM Study. Arterioscler Thromb. 1994;14(9):1412-1419.
36. Lakier JB. Smoking and cardiovascular disease. Am J Med. 1992;93(1A):8S-12S.
37. März W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR. The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Eur Heart J. 2004;25 (23):2109-2119.
38. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337(5):356]. N Engl J Med. 1997; 336(14):973-979.
39. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843.